Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Long-Term Debt Repayments (2016 - 2019)

Enanta Pharmaceuticals' Long-Term Debt Repayments history spans 5 years, with the latest figure at $22000.0 for Q3 2019.

  • For Q3 2019, Long-Term Debt Repayments rose 10.0% year-over-year to $22000.0; the TTM value through Sep 2019 reached $86000.0, up 8.86%, while the annual FY2019 figure was $86000.0, 8.86% up from the prior year.
  • Long-Term Debt Repayments reached $22000.0 in Q3 2019 per ENTA's latest filing, roughly flat from $22000.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $22000.0 in Q2 2019 to a low of $16000.0 in Q4 2015.
  • Average Long-Term Debt Repayments over 5 years is $19125.0, with a median of $19000.0 recorded in 2017.
  • Peak YoY movement for Long-Term Debt Repayments: rose 12.5% in 2016, then grew 5.0% in 2019.
  • A 5-year view of Long-Term Debt Repayments shows it stood at $16000.0 in 2015, then grew by 12.5% to $18000.0 in 2016, then increased by 5.56% to $19000.0 in 2017, then grew by 10.53% to $21000.0 in 2018, then increased by 4.76% to $22000.0 in 2019.
  • Per Business Quant, the three most recent readings for ENTA's Long-Term Debt Repayments are $22000.0 (Q3 2019), $22000.0 (Q2 2019), and $21000.0 (Q1 2019).